Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike
Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.
How this was made
The 30-second read
Why it matters
The collaboration provides a new revenue stream and validates AI‑driven biotech models, potentially expanding TWST's market addressable size.
Market read
The AI partnership and analyst target hike create a short‑term trading catalyst for TWST, with broader implications for biotech‑AI collaborations.
What to watch
Insider Form 4 activity and limited revenue upside from the pilot projects could limit upside.
Background
Twist Bioscience is a synthetic DNA manufacturer that recently linked its wet‑lab services to Eli Lilly's AI drug discovery platform.
Ticker impact
Twist Bioscience announced a partnership with Eli Lilly's AI platform and saw an 8.35% intraday jump, with Leerink raising its price target to $160.
Potential continuation of momentum on pullbacks to prior support; watch for breakout above $180.
The deal links TWST to a major pharma AI stack, and the target raise signals analyst confidence, both likely to attract buying pressure.
Market effects
Highlights growing AI‑driven biotech collaborations, potentially boosting other synthetic biology stocks.
U.S. biotech sector may see heightened interest as AI integration gains visibility.
Sets a precedent for pharma‑biotech AI partnerships worldwide.
Counterpoint
The partnership may be overhyped; TWST remains loss‑making with high cash burn, risking a pullback if results lag.
Key entities
- companyTwist Bioscience
Synthetic DNA producer (NASDAQ: TWST).
- companyEli Lilly
Pharma giant using AI/ML TuneLab platform.
- analystLeerink
Raised TWST price target to $160.
